News
Stay up to date with PredictImmune
Latest News
PredictImmune appoints Tim Rea of BGF as non-executive director
PredictImmune appoints Tim Rea of BGF as non-executive director Experienced entrepreneur and investor appointed with immediate effect Cambridge, UK,...
PredictImmune announces closure of £10 Million series B funding round
PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product pipeline...
Gut publication extends follow-up for PredictImmune’s blood-based prognostic biomarker in IBD.
Gut publication extends follow-up for PredictImmune’s blood-based prognostic biomarker in IBD. Cambridge, UK, 2nd May 2019: Longer-term follow-up...
PredictImmune’s first prognostic test for IBD, PredictSURE IBD™, launches in the UK and Ireland
PredictImmune’s first prognostic test for IBD, PredictSURE IBD™, launches in the UK and Irelandpe The world’s first validated prognostic test for...
PredictImmune’s first prognostic test, PredictSURE IBD™, set for UK and European launch having been awarded CE mark
PredictImmune’s first prognostic test, PredictSURE IBD™, set for UK and European launch having been awarded CE mark Achievement marks significant...
Crohn’s Disease PROFILE Trial Protocol Published
Crohn’s Disease PROFILE Trial Protocol Published Cambridge, UK, 06 December 2018: The PROFILE trial is the first biomarker-stratified study in...
PredictImmune joins the British In Vitro Device Association (BIVDA)
PredictImmune joins the British In vitro Device Association (BIVDA) Cambridge, UK, 13th November 2018: With the launch of its first product...
PredictImmune: Announced as Finalist in the Cambridge Independent Science & Technology Awards
PredictImmune: Announced as Finalist in the Cambridge Independent Science & Technology Awards Cambridge, UK, 14th September 2018: PredictImmune...
PredictImmune joins the Babraham Research Campus community
PredictImmune join the Babraham Research Campus community Developer of pioneering tools for guiding treatment options in immune-mediated...